Turning Point Brands cleared a low bar with room to spare. Adjusted earnings of $0.41 per share beat the $0.33 consensus by 28.1% and topped the $0.32 Earnings Whisper. Revenue rose 27.0% to $151.1 million, 2.8% above expectations. Yet earnings still fell 63.7% from a year ago, and that is the central tension. TPB is buying growth in nicotine pouches at a steep cost to profitability, and this quarter showed that growth beginning to slow while the payoff timeline moves further out.

The quality of the beat deserves scrutiny. GAAP diluted EPS fell to $0.19 from $1.13, and GAAP net income dropped 81.4% to $3.9 million. Part of that gap is a tough comparison: last year's quarter included a $5.5 million employee retention credit refund. Part of it is real cost pressure.

• **Spending:** SG&A jumped 69.1% to $75.3 million on Modern Oral sales and marketing and higher outbound freight. That pushed operating income down to $9.9 million from $25.9 million.
• **Adjusted EBITDA:** fell 41.3% to $18.4 million.
• **Add-backs:** the adjusted figures exclude $3.2 million of FDA PMTA costs and $0.6 million of manufacturing start-up costs. Investors should expect regulatory spending of this kind to recur for some time.
• **Margins:** Stoker's segment gross margin slid to 56.0% from 60.2% as the mix shifted toward lower-margin Modern Oral product.

The top-line engine remains impressive on a year-over-year basis.

• Modern Oral net sales more than doubled, up 102.9% to $74.4 million.
• Gross sales rose 114.2% to $93.9 million.
• The category now makes up 49.2% of company net sales, up from 34% at the end of fiscal 2025.

The sequential picture is less flattering. Modern Oral net sales grew only 9% from the second quarter, compared with 32% in Q2 and 26% in Q1. The reaffirmed full-year range of $260-$270 million implies roughly flat sequential net sales in the fourth quarter.

The guidance language also needs unpacking. The release says guidance was "reaffirmed," but the adjusted EBITDA outlook of $70-$80 million was itself set on September 21 and replaced the $70-$90 million range carried through Q1 and Q2. That makes this the first call of the year without a guidance raise. Year-to-date EBITDA of about $59 million implies a fourth quarter anywhere from $11 million to $21 million. Management acknowledged that at these profit levels a $2-$3 million timing swing materially moves results.

There were genuine positives beneath the surface.

• Adjusted EBITDA improved sequentially from about $15 million in Q2 as SG&A eased.
• Management pared back marketing programs that weren't earning adequate returns. That is prudent, though it also admits some earlier spending was inefficient.
• Heritage Stoker's turned positive at +3% year over year.
• Zig-Zag, down 15.5% year over year, ticked up sequentially to $37.3 million while holding a 57.4% gross margin.
• The FRE brand is rolling into chain accounts won earlier in the year.
• The ALP brand's 7-Eleven test is performing well ahead of spring resets.
• Management reaffirmed more than 70% growth in chain store count.

The bigger setback is manufacturing. Domestic production in Louisville, previously targeted for year-end 2026, has slipped to 2027 with no firm date and depends on FDA timing. That pushes out the roughly 70% gross margin path that underpins the long-term profit case. The company is now preparing a second PMTA listing U.S. manufacturing so the first application keeps its place in the queue.

Cash generation adds to the caution. Free cash flow was only $3.5 million in the quarter. Nine-month operating cash flow fell to $9.4 million from $32.5 million, with inventories up $31.6 million. The balance sheet remains comfortable, with $251.3 million in cash, $48.7 million of net debt, and $322.8 million of liquidity. The company also repurchased $10 million of stock at an average of $59.82, and management said no M&A is expected.

Leadership is new as well. David Glazek, executive chairman for four years, took over as CEO from Graham Purdy and described the strategy as unchanged. However, his team introduced a new framing that the pouch category is "starting to mature," implying a shakeout of smaller players. Several answers on the call also offered no additional transparency.

The market had already repriced the story. Shares entered the report at $65.88, down 23.4% from the $86.00 open after the August report and 23.0% below the 200-day moving average. The stock peaked at $91.94 on August 11. It then slid through the September 21 guidance reset to a 52-week low of $54.17 on October 14, and has since recovered 21.6% off that level. Investor sentiment improved modestly from -0.10 to -0.03 but remains slightly negative. The Earnings Whispers price and AVWAP trend readings are still negative, while sequential growth reads positive.

The bottom line is that TPB delivered a clean beat against diminished expectations, but the quarter weakened the forward narrative more than the headline suggests. Bulls can point to triple-digit Modern Oral growth, sequential EBITDA improvement, and expanding chain distribution. Bears have legitimate ammunition in the lowered EBITDA ceiling, the sharp sequential deceleration, a flat implied fourth quarter, thin free cash flow, and a margin-accretive U.S. manufacturing plan that keeps slipping. The next test is whether chain rollouts reignite sequential growth before the market loses patience with the investment cycle.